H.R. 9774, Expedited OTC Drug Approval Pathway. Quorum's AI analysis reads it as a trade-off: gains for some, costs for others.
H.R. 9774 · Mixed
What it does
This bill creates a new expedited approval pathway for over-the-counter (nonprescription) drugs at the FDA. Drug manufacturers can request 'priority' status for new OTC drugs that address novel health conditions, are new chemical entities, or contain active ingredients never sold OTC before; the FDA must decide within 60 days and then provide accelerated review support including dedicated project leads and collaborative meetings. The bill does not lower safety or efficacy standards—drugs still must meet all existing approval requirements—but streamlines the review process.
The analysis names OTC drug manufacturers — and 2 more groups — among the beneficiaries.
The trade-off
Reliance on 'real world evidence' in place of traditional clinical trials may lower the evidentiary bar for OTC approval, potentially allowing drugs to reach consumers with less rigorous safety/efficacy data than current practice.
Transparency scores 75%, with a medium warning level and no provisions unrelated to the bill's subject.
Who is behind it
Filed by Robert Latta. Cosponsored by Greg Landsman.